Marginal zone lymphoma;
Mucosa-associated lymphoid tissue;
Extranodal marginal zone lymphoma;
Primary cutaneous marginal zone lymphoma;
Rituximab;
Obinutuzumab;
Zanubrutinib;
Case report;
OBINUTUZUMAB;
CLASSIFICATION;
RITUXIMAB;
IBRUTINIB;
CLL;
D O I:
10.12998/wjcc.v12.i3.565
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
BACKGROUND Marginal zone lymphoma (MZL) is an indolent subtype of non-Hodgkin lymphoma (NHL), which is rare clinically with severe rashes as the initial symptom. CASE SUMMARY This study reports a case of MZL with generalized skin rashes accompanied by pruritus and purulent discharge. First-line treatment with rituximab combined with zanubrutinib had poor effects. However, after switching to obinutuzumab combined with zanubrutinib, the case was alleviated, and the rashes disappeared. CONCLUSION For patients with advanced stage MZL not benefiting from type I anti-CD20 monoclonal antibody (mAb) combination therapy, switching to a type II anti-CD20 mAb combination regimen may be considered. This approach may provide a new perspective in the treatment of MZL.
机构:
Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USAUniv Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA
Stueber, Travis
Jaitly, Vanya
论文数: 0引用数: 0
h-index: 0
机构:
Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USAUniv Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA
Jaitly, Vanya
Moore, Erika M.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA
UPMC Presbyterian Hosp, Hill Bldg,Room 357,3477 Euler Way, Pittsburgh, PA 15213 USAUniv Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA